Prophylactic use of topical adriamycin after transurethral resection of transitional cell bladder tumours.
Thirty-five patients with carcinoma of the bladder were subjected to weekly intravesical instillation treatment with 30 mg adriamycin/50 ml solution for a period of 6 weeks following transurethral resection of the tumour. The oncolytic and thus recurrence-preventive value of treatment was determined by endoscopic controls with exploratory excisions and exfoliative cytology. All in all, a recurrence-free rate was found in 77% over a minimum observation period of one year. These results are definitely better than those of comparable instillation treatments with surface-active or immunologically active substances.
D000287:Administration, Topical; D000328:Adult; D000368:Aged; D002295:Carcinoma, Transitional Cell / Q000601:surgery*; D004317:Doxorubicin / Q000008:administration & dosage / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009364:Neoplasm Recurrence, Local / Q000517:prevention & control*; D014521:Urethra / Q000601:surgery; D001749:Urinary Bladder Neoplasms / Q000601:surgery*
D004317:Doxorubicin